Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

City of Hope Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving ...

Alicia Morgans, MD, MPH, discusses how the ARANOTE trial not only demonstrated clinical efficacy for the combination of ADT and darolutamide, but also highlighted key quality-of-life benefits that ...

Hone Health reports that the controversial 2002 WHI study misled menopause care, linking HRT to breast cancer and causing ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Researchers reviewed cases in which patients experienced severe skin toxicities in response to immunotherapy, and sought to identify the distinct natures of these toxicities.

The best at-home, FDA-approved red light therapy tools and panels for the face and body in 2025, according to editors, ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

Panelists discuss how newer immune-based therapies and bispecific antibodies may enable fixed-duration treatment approaches that could eliminate the need for stem cell transplant in older but fit ...

Overview of Plasma Therapy MarketThe global Plasma Therapy Market is valued at USD 354.33 Billion in 2024 and is projected to reach a value of USD 1575 Billion by 2035 at a CAGR (Compound Annual ...